PIM2 and Miyoshi myopathy: Also, Jumpei Teramachi et al. reported that TAK1 combined with PIM2, the promotor of MM cell growth and survival, not only can be used as anti-apoptotic mediators in MM, but also be upregulated by inhibitors such as TGF-β and activin A for osteoblastogenesis [4, 13].